At the National People's Congress and the National People's Congress, Xiao Wei, academician of the Chinese Academy of Engineering, and chairman of Kangyuan Group, suggested that the development of ancient classic prescriptions into new Chinese patent medicines should be encouraged and the expansion of clinical use scenarios should be supported.
In today's society, with the growing demand for health, traditional Chinese medicine, as a treasure of the Chinese nation, is developing with unique charm and innovation. Innovation is the key to the future of traditional Chinese medicine, and it is necessary to establish a bridge between traditional Chinese medicine and modern science, use the continuous development of modern science to clarify the mechanism of traditional Chinese medicine, and form an innovative mechanism for the development of traditional Chinese medicine.
Ancient classic formulas are the source of inheritance and innovation of traditional Chinese medicine, and through the development and production of modern scientific and technological means, these classic formulas can be transformed into traditional Chinese patent medicines with modern preparation technology and quality standards, so as to better meet clinical needs. Xiao Wei of Kangyuan Group said.
As an important carrier of the interconnection between traditional theories of traditional Chinese medicine and modern medical theories, proprietary Chinese medicine has the advantages of engineering production and group application. However, at present, the development of the Chinese patent medicine industry is still facing great pressure and challenges. According to the statistics of the China Pharmaceutical Industry Information Center, the proportion of the Chinese medicine industry in the pharmaceutical industry has been declining year by year, from about 29% to about 22%. In clinical application, there is still a phenomenon of discrimination and exclusion of proprietary Chinese medicines, which makes the clinical status of proprietary Chinese medicines not fully reflected.
Xiao Wei of Kangyuan Group emphasized that public hospitals at all levels should eliminate discrimination against proprietary Chinese medicines, especially innovative Chinese medicines, and cancel all kinds of restrictions on the use of proprietary Chinese medicines. He mentioned that the research and development of proprietary Chinese medicines, especially innovative Chinese patent medicines, are in line with strict technical guidelines and the requirements of laws and regulations, and there are clear "functional indications" of traditional Chinese medicine and "clinical indications" of western medicine, so that clinicians of both traditional Chinese medicine and western medicine can understand and use diseases.
Xiao Wei of Kangyuan Group also pays special attention to the safety of children's medication. He pointed out that the current pediatric drug market has problems such as few varieties and inaccurate dosages, which fail to meet the actual clinical needs of children's drugs. Xiao Wei of Kangyuan Group called for strengthening the R&D and production of Chinese patent medicines for children, and developing more safe, effective and convenient Chinese patent medicine products for the drug needs of children of different ages.
As a first-line enterprise of traditional Chinese medicine innovation, Kangyuan Group should also dig deep into the essence of the treasure house of traditional Chinese medicine, and at the same time combine modern scientific and technological means to promote the application of traditional Chinese medicine in clinical practice, product research and development, etc., and contribute Chinese wisdom and Chinese solutions to the global health cause.
Disclaimer: The market is risky, choose carefully! This article is for reference only and is not intended as a basis for trading.